Astria Therapeutics, Inc.2025财年第一财季实现净利润-33.71百万美元，同比减少69.14%

市场透视2025-05-20

5月20日，Astria Therapeutics, Inc.（ATXS.US）公布财报，公告显示公司2025财年第一财季净利润为-33.71百万美元，同比减少69.14%；其中营业收入为0.00美元，每股基本收益为-0.58美元。从资产负债表来看，Astria Therapeutics, Inc.（ATXS.US）总负债21.10百万美元，其中短期债务1.39百万美元，资产负债比为0.15，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2536636681?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-20 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2536636681","market":"us","top_or_hot":-1,"title":"Astria Therapeutics, Inc.2025财年第一财季实现净利润-33.71百万美元，同比减少69.14%","media":"市场透视","content":"<div>\n<p>5月20日，Astria Therapeutics, Inc.（ATXS.US）公布财报，公告显示公司2025财年第一财季净利润为-33.71百万美元，同比减少69.14%；其中营业收入为0.00美元，每股基本收益为-0.58美元。从资产负债表来看，Astria Therapeutics, Inc.（ATXS.US）总负债21.10百万美元，其中短期债务1.39百万美元，资产负债比为0.15，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520000100a6e4effc&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Astria Therapeutics, Inc.2025财年第一财季实现净利润-33.71百万美元，同比减少69.14%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstria Therapeutics, Inc.2025财年第一财季实现净利润-33.71百万美元，同比减少69.14%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-20 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520000100a6e4effc&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月20日，Astria Therapeutics, Inc.（ATXS.US）公布财报，公告显示公司2025财年第一财季净利润为-33.71百万美元，同比减少69.14%；其中营业收入为0.00美元，每股基本收益为-0.58美元。从资产负债表来看，Astria Therapeutics, Inc.（ATXS.US）总负债21.10百万美元，其中短期债务1.39百万美元，资产负债比为0.15，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520000100a6e4effc&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520000100a6e4effc&s=b","article_id":"2536636681","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520000100a6e4effc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2536636681","pubTimestamp":1747670435,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月20日，Astria Therapeutics, Inc.公布财报，公告显示公司2025财年第一财季净利润为-33.71百万美元，同比减少69.14%；其中营业收入为0.00美元，每股基本收益为-0.58美元。机构评级：截至2025年5月20日，当前有9家机构对Astria Therapeutics, Inc.目标价做出预测，其中目标均价为28.67美元，其中最低目标价为16.00美元，最高目标价为47.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","ATXS":"Astria Therapeutics Inc"},"translate_title":"Astria Therapeutics, Inc. achieved net profit of-US $33.71 million in the first fiscal quarter of fiscal year 2025, a year-on-year decrease of 69.14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"ATXS":0.9},"content_text":"5月20日，Astria Therapeutics, Inc.（ATXS.US）公布财报，公告显示公司2025财年第一财季净利润为-33.71百万美元，同比减少69.14%；其中营业收入为0.00美元，每股基本收益为-0.58美元。从资产负债表来看，Astria Therapeutics, Inc.（ATXS.US）总负债21.10百万美元，其中短期债务1.39百万美元，资产负债比为0.15，流动比率为0.18。机构评级：截至2025年5月20日，当前有9家机构对Astria Therapeutics, Inc.目标价做出预测，其中目标均价为28.67美元，其中最低目标价为16.00美元，最高目标价为47.00美元。公司简介：Astria Therapeutics Inc是一家生物制药公司，致力于为受罕见和小众过敏和免疫疾病影响的患者和家庭带来改变生活的疗法。公司其中一个项目STAR-0215是一种用于治疗遗传性血管性水肿的血浆钾激肽单克隆抗体抑制剂，处于临床前开发阶段。公司的第二个候选产品是STAR-0310，这是一种单克隆抗体OX40拮抗剂，处于临床前开发阶段，用于治疗特应性皮炎（AD），一种与皮肤屏障功能丧失和瘙痒相关的免疫疾病。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2536636681","isCrawlerRequest":true}